Format

Send to:

Choose Destination
See comment in PubMed Commons below
Lung Cancer. 2010 Feb;67(2):194-7. doi: 10.1016/j.lungcan.2009.03.031. Epub 2009 May 5.

Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma.

Author information

  • 1Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Nagaizumi, Shizuoka 411-8777, Japan.

Abstract

BACKGROUND:

Thymic carcinoma is a very rarely encountered neoplasm and no optimal chemotherapeutic regimen has been established yet.

METHODS:

The records of previously untreated thymic carcinoma patients with unresectable disease who had been treated with paclitaxel and carboplatin as first-line chemotherapy between 2003 and 2008 were reviewed, retrospectively. Paclitaxel was administered at the dose of 200mg/m(2) and carboplatin at an AUC of 6 on day 1, with the treatment cycle repeated every 3 weeks.

RESULTS:

Eleven patients were registered, and a total of 45 cycles of carboplatin/paclitaxel were administered (median cycles per patient, 4; range, 2-6). Although the principal toxicity of this regimen was neutropenia, with grade 3 or more severe neutropenia being observed in nine patients (82%), there were no cases of febrile neutropenia. There were also no cases of grade 3 or more severe peripheral sensory neuropathy. Thus, the toxicity profile of the treatment regimen was acceptable. The overall response rate was 36%, and the median survival time and median progression-free survival were 22.7 months and 7.9 months, respectively.

CONCLUSION:

Combined paclitaxel+carboplatin therapy exhibits activity and acceptable toxicity in the first-line setting in patients with unresectable thymic carcinoma.

Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

PMID:
19409644
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk